Skip to main content
. Author manuscript; available in PMC: 2009 Jun 8.
Published in final edited form as: Eur J Neurosci. 2009 Mar;29(6):1119–1130. doi: 10.1111/j.1460-9568.2009.06664.x

FIG. 8.

FIG. 8

Effects of murine recombinant 3K3A-APC and wt-APC on functional recovery and infarct volume after permanent dMCAO. Vehicle, murine wt-APC (0.2 mg/kg) or murine 3K3A-APC (0.2 mg/kg) was administered via the tail vein at multiple times at 12:00 h, 1, 3, 5 and 7 days after permanent dMCAO. Functional tests and infarct volume were determined within 7 days (D) of dMCAO. (a) Foot-fault test. (b) Forelimb asymmetry test. (c) Cresyl violet staining of brain coronal sections of ischemic mice treated with vehicle or 3K3A-APC for 7 days after dMCAO. (d) Infarct volume. (e) Hemoglobin levels in the ischemic hemisphere of mice treated with vehicle, wt-APC or 3K3A-APC for 7 days after dMCAO. All values are mean + SEM. aP < 0.01, for 3K3A-APC vs. wt-APC; bP < 0.01, for 3K3A-APC vs. vehicle by repeated-measures ANOVA.